Recent 8-K filings for PRGO

• May 06, 2026 23:59 UTC earnings materiality 0.75 negative item 2.02item 9.01

  Perrigo Q1 net sales $969M (-7.2%), adj EPS $0.43 (-28%); reaffirms FY 2026 outlook

  All In net sales $969M, down 7.2% YoY; reported diluted EPS $(2.81) due to $330.8M goodwill impairment.

• May 05, 2026 23:59 UTC other materiality 0.50 neutral item 5.02item 5.07item 9.01

  Perrigo shareholders approve 2026 LTIP, re-elect all director nominees at AGM

  2026 Long-Term Incentive Plan approved (101.5M for); replaces 2019 Plan. Authorized pool: 7.265M new shares plus forfeitures.

• Apr 30, 2026 23:59 UTC m_and_a materiality 0.75 neutral item 2.01item 7.01item 9.01

  Perrigo completes sale of Dermacosmetics business for €305.6M upfront, plus contingent €27M

  Upfront cash €305.6M (incl. €5.6M working capital); up to €27M contingent on net sales milestones over three years.

• Apr 22, 2026 23:59 UTC other_material materiality 0.75 negative item 2.02item 7.01item 8.01item 9.01

  Perrigo revises segment reporting; FY2025 includes $1.36B impairment charge

  Self Care segment net sales $2,533.5M in FY2025, down from $2,554.3M in FY2024.

• Mar 23, 2026 23:59 UTC debt materiality 0.55 neutral item 1.01item 2.03item 9.01

  Perrigo amends credit facility: $1.0B revolver (2031) & $972M term loan B (2029)

  Entered Amended and Restated Credit Agreement on March 20, 2026, with JPMorgan and others.

• Feb 26, 2026 23:59 UTC earnings materiality 0.90 negative item 2.02item 9.01

  Perrigo Q4 adj. EPS $0.77 vs $0.93 YoY; records $1.3B goodwill impairment; FY2026 outlook $2.00-$2.30

  Q4 net sales $1.11B (-2.5% YoY); reported EPS ($10.20) from $1.3B goodwill impairment.

• Nov 05, 2025 23:59 UTC earnings materiality 0.80 negative item 2.02item 7.01item 9.01

  Perrigo Q3 adj EPS $0.80 flat YoY; cuts FY25 guide; starts infant formula review

  Q3 net sales $1.04B (-4.1% YoY); adj EPS $0.80 vs $0.81; reported EPS $0.09 vs -$0.13.

• Aug 06, 2025 23:59 UTC earnings materiality 0.70 neutral item 2.02item 9.01

  Perrigo Q2 2025 Adj EPS $0.57 beats $0.53; net sales $1.06B down 0.9% YoY

  Reported EPS $0.00 vs $(0.77); Adj EPS $0.57 up 7.5% YoY on lower interest expense from reduced debt.

• Jul 14, 2025 23:59 UTC m_and_a materiality 0.75 positive item 1.01item 7.01item 9.01

  Perrigo to sell Dermacosmetics business to KKR for up to €327M

  Upfront cash €300M, plus up to €27M milestone payments over three years.

• Jul 01, 2025 23:59 UTC leadership materiality 0.60 neutral item 5.02item 7.01item 9.01

  Perrigo restructures leadership; Triona Schmelter departs, Roberto Khoury named EVP & CCO

  Triona Schmelter, EVP & President Consumer Self-Care Americas, departs June 30 due to position elimination; remains advisory until Oct 31.

• Jun 04, 2025 23:59 UTC leadership materiality 0.55 neutral item 5.02item 7.01item 9.01

  Perrigo EVP Global Ops Ron Janish to retire; Matt Winterman appointed as successor

  Ron Janish steps down June 23, 2025; advisory role through Sep 30, 2025.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.90 · Median 0.75 · Most common event earnings

1 positive 4 negative 6 neutral

source · PRGO on sec.gov